Agilent Technologies (NYSE:A) Price Target Raised to $140.00

Agilent Technologies (NYSE:A) had its price target lifted by Wells Fargo & Company from $135.00 to $140.00 in a report issued on Thursday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical research company’s stock.

A number of other brokerages have also commented on A. Evercore ISI dropped their price target on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating on the stock in a report on Thursday. Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, June 28th. Barclays increased their price objective on Agilent Technologies from $115.00 to $125.00 and gave the company an “equal weight” rating in a report on Tuesday, June 24th. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 29th. Finally, UBS Group cut their price target on Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $139.25.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $125.63 on Thursday. The business’s fifty day simple moving average is $118.39 and its 200 day simple moving average is $116.50. The firm has a market capitalization of $35.69 billion, a P/E ratio of 29.49, a price-to-earnings-growth ratio of 3.82 and a beta of 1.22. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a current ratio of 2.25, a quick ratio of 1.60 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same period last year, the company posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Investors Weigh In On Agilent Technologies

Large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after buying an additional 4,362 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock worth $3,606,000 after buying an additional 2,371 shares during the period. Alps Advisors Inc. increased its holdings in shares of Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after buying an additional 3,040 shares during the period. D.A. Davidson & CO. increased its holdings in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after buying an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. increased its holdings in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after buying an additional 54,302 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.